Question from Deputy Ken O'Flynn - PQ 13632-26
Deputy O'Flynn asked about the total expenditure incurred in 2024 and 2025 on salbutamol nebules and equivalent substitute product. Read the HSE response.
- Published date:
- :
Browse and read HSE's latest publications, which include strategic plans, reports, official policies and codes, Parliamentary Question (PQ) responses, and board meeting minutes.
Deputy O'Flynn asked about the total expenditure incurred in 2024 and 2025 on salbutamol nebules and equivalent substitute product. Read the HSE response.
Deputy Rice asked about the publication of a comprehensive framework outlining a programme for the diagnosis and treatment of premenstrual dysphoric disorder.
Deputy O'Flynn asked about the recruitment of consultants for the child and adolescent gender-related service. Read the HSE response.
Deputy O'Flynn asked about the recruitment control measures introduced in 2023 and 2024. Read the HSE response.
Deputy Rice asked if GPs have been provided with guidelines for the diagnosis and treatment of premenstrual dysphoric disorder. Read the HSE response.
Ken O'Flynn asked will the findings of the Cass Review be incorporated in the review of the National Gender Service Model of Care (2018). Read the HSE response.
Deputy O'Flynn asked about the clinical governance arrangements that apply to specialist gender healthcare services. Read the HSE response.
Deputy Ó Súilleabháin asked about the funding of mental health services in Wexford. Read the HSE response.
Deputy O'Flynn asked about reimbursement claims for salbutamol nebules or equivalent short-acting bronchodilator nebule products. Read the HSE response.
Deputy O'Flynn asked about the administrative burden placed on community pharmacies when substitute reimbursement must be queried. Read the HSE response.